Form 8-K - Current report:
SEC Accession No. 0000950170-25-076304
Filing Date
2025-05-22
Accepted
2025-05-22 16:05:54
Documents
10
Period of Report
2025-05-22
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K dnth-20250522.htm   iXBRL 8-K 72721
  Complete submission text file 0000950170-25-076304.txt   222464

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT dnth-20250522.xsd EX-101.SCH 57693
12 EXTRACTED XBRL INSTANCE DOCUMENT dnth-20250522_htm.xml XML 4698
Mailing Address 7 TIMES SQUARE 43RD FLOOR NEW YORK NY 10036
Business Address 7 TIMES SQUARE 43RD FLOOR NEW YORK NY 10036 929-999-4055
Dianthus Therapeutics, Inc. /DE/ (Filer) CIK: 0001690585 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38541 | Film No.: 25977077
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)